<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02344680</url>
  </required_header>
  <id_info>
    <org_study_id>F150819001</org_study_id>
    <secondary_id>1K01TW009998</secondary_id>
    <nct_id>NCT02344680</nct_id>
  </id_info>
  <brief_title>Liver Fibrosis in Zambian HIV-HBV Co-infected Patients</brief_title>
  <official_title>Liver Fibrosis in Zambian HIV-HBV Co-infected Patients: a Long-term Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>John E. Fogarty International Center (FIC)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators will determine risk factors for liver fibrosis among HIV-HBV
      co-infected patients in Lusaka, Zambia, and assess the long-term effectiveness of
      antiretroviral drugs in the prevention and/or reduction of liver disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Among HIV-infected individuals in Africa, liver disease is a neglected area of investigation
      but is anticipated to become increasingly common as patients live longer due to
      antiretroviral therapy. In a currently approved and active research study taking place in
      Lusaka Urban district - HIV/HBV co-infection in IeDEA-SA (NCT02060162, clinicaltrials.gov) -
      800 consecutive HIV-infected adults were screened for possible causes of liver disease and
      12% were diagnosed with chronic hepatitis B virus (HBV) co-infection. HBV co-infected
      patients were more likely to have evidence of liver disease; however, ascertainment of
      critical long-term outcomes of HIV-HBV patients was not part of the study. Building on these
      preliminary results and addressing the need to study HIV-HBV during a longer duration of
      follow-up, the current protocol will focus exclusively on Zambian HIV-HBV patients. In the
      proposed study, the investigators will determine the risk factors for liver disease among
      Zambian HIV-HBV co-infected patients, and assess the long-term effectiveness of Ministry of
      Health (MOH)-recommended antiretroviral drugs in the prevention and/or reduction of HIV-HBV
      liver disease. This study will provide useful clinical and epidemiologic information to
      health policymakers in Zambia and throughout the region and may lead to improvements in the
      care of HIV-HBV patients. Further, it will strengthen collaboration between Zambian
      institutions and strengthen local capacity in HBV diagnosis and management.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in liver fibrosis stage</measure>
    <time_frame>From baseline to month 48</time_frame>
    <description>Measure of liver fibrosis using AST-to-platelet ratio index (APRI), Fibrosis 4 (FIB-4) and transient elastography. Ascertainment of potential risk factors including demographics, alcohol use, HIV-related biomarkers, HBV DNA, hepatitis delta virus, and other factors.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of hepatocellular carcinoma</measure>
    <time_frame>From baseline to month 48</time_frame>
    <description>Liver cancer screening at baseline and during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of significant liver fibrosis (Metavir F2 or greater)</measure>
    <time_frame>At enrollment</time_frame>
    <description>Measure of liver fibrosis using AST-to-platelet ratio index (APRI), Fibrosis 4 (FIB-4) and transient elastography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors for persistent HBV viremia 9Measure HBV DNA at baseline and month 12 and determine patient characteristics associated with unsuppressed HBV after 12 months of treatment)</measure>
    <time_frame>Month 12</time_frame>
    <description>Measure HBV DNA at baseline and month 12 and determine patient characteristics associated with unsuppressed HBV after 12 months of treatment</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <condition>HBV</condition>
  <condition>Fibrosis, Liver</condition>
  <condition>Cirrhosis, Liver</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Hepatitis Delta Virus</condition>
  <condition>Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>HIV-HBV co-infected</arm_group_label>
    <description>HIV-HBV co-infected patients receiving anti-retroviral therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-HIV Agents</intervention_name>
    <arm_group_label>HIV-HBV co-infected</arm_group_label>
    <other_name>Anti-retroviral therapy</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        400 HIV-HBV patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  HIV-infected

          -  HBV-infected, defined as any single positive HBsAg assay

          -  Naïve to antiretroviral therapy or currently participating in HIV/HBV co-infection in
             IeDEA-SA

        Exclusion Criteria:

          -  Unable or unwilling to provide informed consent

          -  Planning to relocate out of Lusaka district
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J Vinikoor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Vinikoor</last_name>
    <phone>260 972921285</phone>
    <email>michael.vinikoor@cidrz.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roma Chilengi</last_name>
    <email>roma.chilengi@cidrz.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre for Infectious Disease Research in Zambia (CIDRZ)</name>
      <address>
        <city>Lusaka</city>
        <zip>34681</zip>
        <country>Zambia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Vinikoor</last_name>
      <phone>260 972921285</phone>
      <email>michael.vinikoor@cidrz.org</email>
    </contact>
    <contact_backup>
      <last_name>Izukanji Sikazwe</last_name>
      <email>izukanji.sikazwe@cidrz.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Zambia</country>
  </location_countries>
  <link>
    <url>http://globalhealth.unc.edu</url>
    <description>Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill (U.S.A.)</description>
  </link>
  <reference>
    <citation>Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, De Wit S, Akerlund B, Calvo G, Monforte Ad, Rickenbach M, Ledergerber B, Phillips AN, Lundgren JD. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006 Aug 14-28;166(15):1632-41.</citation>
    <PMID>16908797</PMID>
  </reference>
  <reference>
    <citation>Central Statistical Office (CSO) MoH, Tropical Diseases Research Centre, University of Zambia, and Macro International Inc. Zambia Demographic and Health Survey 2007. Calverton, Maryland, USA: CSO and Macro International Inc., 2009.</citation>
  </reference>
  <reference>
    <citation>Kapembwa KC, Goldman JD, Lakhi S, Banda Y, Bowa K, Vermund SH, Mulenga J, Chama D, Chi BH. HIV, Hepatitis B, and Hepatitis C in Zambia. J Glob Infect Dis. 2011 Jul;3(3):269-74. doi: 10.4103/0974-777X.83534.</citation>
    <PMID>21887060</PMID>
  </reference>
  <reference>
    <citation>Hamers RL, Zaaijer HL, Wallis CL, Siwale M, Ive P, Botes ME, Sigaloff KC, Hoepelman AI, Stevens WS, Rinke de Wit TF; PharmAccess African Studies to Evaluate Resistance (PASER). HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes. J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):174-82. doi: 10.1097/QAI.0b013e3182a60f7d.</citation>
    <PMID>23892239</PMID>
  </reference>
  <reference>
    <citation>Martín-Carbonero L, Teixeira T, Poveda E, Plaza Z, Vispo E, González-Lahoz J, Soriano V. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. AIDS. 2011 Jan 2;25(1):73-9. doi: 10.1097/QAD.0b013e328340fde2.</citation>
    <PMID>21076274</PMID>
  </reference>
  <reference>
    <citation>Tuma P, Medrano J, Resino S, Vispo E, Madejón A, Sánchez-Piedra C, Rivas P, Labarga P, Martín-Carbonero L, Barreiro P, Soriano V. Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy. Antivir Ther. 2010;15(6):881-6. doi: 10.3851/IMP1630.</citation>
    <PMID>20834100</PMID>
  </reference>
  <reference>
    <citation>Kirk GD, Bah E, Montesano R. Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from The Gambia, West Africa. Carcinogenesis. 2006 Oct;27(10):2070-82. Epub 2006 May 5. Erratum in: Carcinogenesis. 2006 Dec;27(12):2565.</citation>
    <PMID>16679307</PMID>
  </reference>
  <reference>
    <citation>Stabinski L, Reynolds SJ, Ocama P, Laeyendecker O, Ndyanabo A, Kiggundu V, Boaz I, Gray RH, Wawer M, Thio C, Thomas DL, Quinn TC, Kirk GD; Rakai Health Sciences Program. High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir Ther. 2011;16(3):405-11. doi: 10.3851/IMP1783.</citation>
    <PMID>21555823</PMID>
  </reference>
  <reference>
    <citation>Crane M, Iser D, Lewin SR. Human immunodeficiency virus infection and the liver. World J Hepatol. 2012 Mar 27;4(3):91-8. doi: 10.4254/wjh.v4.i3.91.</citation>
    <PMID>22489261</PMID>
  </reference>
  <reference>
    <citation>Puoti M, Manno D, Nasta P, Carosi G. Hepatitis B virus and HIV coinfection in low-income countries: unmet needs. Clin Infect Dis. 2008 Feb 1;46(3):367-9. doi: 10.1086/525532.</citation>
    <PMID>18171305</PMID>
  </reference>
  <reference>
    <citation>Hoffmann CJ, Charalambous S, Martin DJ, Innes C, Churchyard GJ, Chaisson RE, Grant AD, Fielding KL, Thio CL. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis. 2008 Dec 1;47(11):1479-85. doi: 10.1086/593104.</citation>
    <PMID>18937580</PMID>
  </reference>
  <reference>
    <citation>Hawkins C, Christian B, Ye J, Nagu T, Aris E, Chalamilla G, Spiegelman D, Mugusi F, Mehta S, Fawzi W. Prevalence of hepatitis B co-infection and response to antiretroviral therapy among HIV-infected patients in Tanzania. AIDS. 2013 Mar 27;27(6):919-27. doi: 10.1097/QAD.0b013e32835cb9c8.</citation>
    <PMID>23196935</PMID>
  </reference>
  <reference>
    <citation>Wandeler G, Gsponer T, Bihl F, Bernasconi E, Cavassini M, Kovari H, Schmid P, Battegay M, Calmy A, Egger M, Furrer H, Rauch A; Swiss HIV Cohort Study. Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study. J Infect Dis. 2013 Nov 1;208(9):1454-8. doi: 10.1093/infdis/jit351. Epub 2013 Jul 30.</citation>
    <PMID>23901088</PMID>
  </reference>
  <reference>
    <citation>Easterbrook P, Sands A, Harmanci H. Challenges and priorities in the management of HIV/HBV and HIV/HCV coinfection in resource-limited settings. Semin Liver Dis. 2012 May;32(2):147-57. doi: 10.1055/s-0032-1316476. Epub 2012 Jul 3. Review.</citation>
    <PMID>22760654</PMID>
  </reference>
  <reference>
    <citation>Kelly P, Saloojee H, Chen JY, Chung RT. Noncommunicable diseases in HIV infection in low- and middle-income countries: gastrointestinal, hepatic, and nutritional aspects. J Acquir Immune Defic Syndr. 2014 Sep 1;67 Suppl 1:S79-86. doi: 10.1097/QAI.0000000000000260. Review.</citation>
    <PMID>25117963</PMID>
  </reference>
  <reference>
    <citation>Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008 Feb;48(2):335-52. Epub 2007 Dec 4. Review.</citation>
    <PMID>18096267</PMID>
  </reference>
  <reference>
    <citation>Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. J Hepatol. 2006;44(1 Suppl):S65-70. Epub 2005 Nov 28. Review.</citation>
    <PMID>16338021</PMID>
  </reference>
  <reference>
    <citation>Thio CL. Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. Semin Liver Dis. 2003 May;23(2):125-36. Review.</citation>
    <PMID>12800066</PMID>
  </reference>
  <reference>
    <citation>Lok AS. Chronic hepatitis B. N Engl J Med. 2002 May 30;346(22):1682-3.</citation>
    <PMID>12037146</PMID>
  </reference>
  <reference>
    <citation>Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis. 2007 Jun;7(6):402-9. Review.</citation>
    <PMID>17521593</PMID>
  </reference>
  <reference>
    <citation>Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Muñoz A, Thomas DL; Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002 Dec 14;360(9349):1921-6.</citation>
    <PMID>12493258</PMID>
  </reference>
  <reference>
    <citation>Zambian Ministry of Health. Guidelines for the care of individuals with HIV/AIDS, 2010.</citation>
  </reference>
  <reference>
    <citation>Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva: World Health Organization; 2013 Jun.</citation>
    <PMID>24716260</PMID>
  </reference>
  <reference>
    <citation>Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006 Jun;43(6):1317-25.</citation>
    <PMID>16729309</PMID>
  </reference>
  <reference>
    <citation>Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003 Aug;38(2):518-26.</citation>
    <PMID>12883497</PMID>
  </reference>
  <reference>
    <citation>Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis C, Ziol M, Poulet B, Kazemi F, Beaugrand M, Palau R. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003 Dec;29(12):1705-13.</citation>
    <PMID>14698338</PMID>
  </reference>
  <reference>
    <citation>Hawkins C, Agbaji O, Ugoagwu P, Thio CL, Auwal MM, Ani C, Okafo C, Wallender E, Murphy RL. Assessment of liver fibrosis by transient elastography in patients with HIV and hepatitis B virus coinfection in Nigeria. Clin Infect Dis. 2013 Dec;57(12):e189-92. doi: 10.1093/cid/cit564. Epub 2013 Sep 6.</citation>
    <PMID>24014732</PMID>
  </reference>
  <reference>
    <citation>Bonnard P, Sombié R, Lescure FX, Bougouma A, Guiard-Schmid JB, Poynard T, Calès P, Housset C, Callard P, Le Pendeven C, Drabo J, Carrat F, Pialoux G. Comparison of elastography, serum marker scores, and histology for the assessment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina Faso. Am J Trop Med Hyg. 2010 Mar;82(3):454-8. doi: 10.4269/ajtmh.2010.09-0088.</citation>
    <PMID>20207872</PMID>
  </reference>
  <reference>
    <citation>Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013 Feb 9;381(9865):468-75. doi: 10.1016/S0140-6736(12)61425-1. Epub 2012 Dec 10.</citation>
    <PMID>23234725</PMID>
  </reference>
  <reference>
    <citation>Cardoso AC, Carvalho-Filho RJ, Stern C, Dipumpo A, Giuily N, Ripault MP, Asselah T, Boyer N, Lada O, Castelnau C, Martinot-Peignoux M, Valla DC, Bedossa P, Marcellin P. Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C. Liver Int. 2012 Apr;32(4):612-21. doi: 10.1111/j.1478-3231.2011.02660.x. Epub 2011 Nov 22.</citation>
    <PMID>22103765</PMID>
  </reference>
  <reference>
    <citation>Miailhes P, Pradat P, Chevallier M, Lacombe K, Bailly F, Cotte L, Trabaud MA, Boibieux A, Bottero J, Trepo C, Zoulim F. Proficiency of transient elastography compared to liver biopsy for the assessment of fibrosis in HIV/HBV-coinfected patients. J Viral Hepat. 2011 Jan;18(1):61-9. doi: 10.1111/j.1365-2893.2010.01275.x.</citation>
    <PMID>20196798</PMID>
  </reference>
  <reference>
    <citation>Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med. 1998 Sep 14;158(16):1789-95.</citation>
    <PMID>9738608</PMID>
  </reference>
  <reference>
    <citation>Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addiction. 1993 Jun;88(6):791-804.</citation>
    <PMID>8329970</PMID>
  </reference>
  <reference>
    <citation>Vinikoor MJ, Schuttner L, Moyo C, Li M, Musonda P, Hachaambwa LM, Stringer JS, Chi BH. Short communication: Late refills during the first year of antiretroviral therapy predict mortality and program failure among HIV-infected adults in urban Zambia. AIDS Res Hum Retroviruses. 2014 Jan;30(1):74-7. doi: 10.1089/AID.2013.0167. Epub 2013 Aug 30.</citation>
    <PMID>23924188</PMID>
  </reference>
  <reference>
    <citation>Kim BK, Fung J, Yuen MF, Kim SU. Clinical application of liver stiffness measurement using transient elastography in chronic liver disease from longitudinal perspectives. World J Gastroenterol. 2013 Mar 28;19(12):1890-900. doi: 10.3748/wjg.v19.i12.1890. Review.</citation>
    <PMID>23569334</PMID>
  </reference>
  <reference>
    <citation>The Zambian National Health Research Bill, 2013</citation>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2015</study_first_submitted>
  <study_first_submitted_qc>January 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>May 22, 2017</last_update_submitted>
  <last_update_submitted_qc>May 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Michael Vinikoor</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
    <mesh_term>Hepatitis D</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-HIV Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

